Inventor · disambiguated record
Brooks Boyd
Also filed as: BOYD BROOKS · BOYD BROOKS M
21 granted patents·32 pending applications·149 citations·filing 2002–2022
95Inventor score
Top patents by PatentIndex Score
53 records- 0198US11325882B2Metabolism resistant fenfluramine analogs and methods of using the sameZOGENIX INTERNATIONAL LTD·Filed 2020·Granted May 10, 2022·4 cites·3 claims
- 0298US11040018B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2020·Granted Jun 22, 2021·10 cites·9 claims
- 0397US11673852B2Metabolism resistant fenfluramine analogs and methods of using the sameZOGENIX INTERNATIONAL LTD·Filed 2022·Granted Jun 13, 2023·2 cites·4 claims
- 0497US11406606B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2022·Granted Aug 9, 2022·5 cites·22 claims
- 0596US11759440B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2021·Granted Sep 19, 2023·3 cites·10 claims
- 0694US11786487B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2021·Granted Oct 17, 2023·2 cites·9 claims
- 0794US11458111B2Ketogenic diet compatible fenfluramine formulationZOGENIX INTERNATIONAL LTD·Filed 2020·Granted Oct 4, 2022·5 cites·26 claims
- 0894US10689324B2Metabolism resistant fenfluramine analogs and methods of using the sameZOGENIX INTERNATIONAL LTD·Filed 2016·Granted Jun 23, 2020·11 cites·3 claims
- 0994US10603290B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Mar 31, 2020·10 cites·10 claims
- 1092US9186461B2Viscous formulations and their use in needle-free injectionBOYD BROOKS M·Filed 2012·Granted Nov 17, 2015·14 cites·31 claims
- 1192US8876758B2Viscous formulations and their use in needle-free injectionBOYD BROOKS M·Filed 2011·Granted Nov 4, 2014·13 cites·34 claims
- 1290US10682317B2Ketogenic diet compatible fenfluramine formulationZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Jun 16, 2020·10 cites·11 claims
- 1389US9737605B2Injectable controlled release composition comprising high viscosity liquid carrierDURECT CORP·Filed 2014·Granted Aug 22, 2017·11 cites·23 claims
- 1489US8066661B2Viscous formulations and their use in needle-free injectionBOYD BROOKS M·Filed 2008·Granted Nov 29, 2011·14 cites·4 claims
- 1585US8734384B2Needle-free injectors and design parameters thereof that optimize injection performanceBOYD BROOKS·Filed 2011·Granted May 27, 2014·20 cites·19 claims
- 1684US10226532B2Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2017·Granted Mar 12, 2019·3 cites·20 claims
- 1781US9572812B2Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2016·Granted Feb 21, 2017·3 cites·20 claims
- 1878US9662449B2Needle-free injectors and design parameters thereof that optimize injection performanceZOGENIX INC·Filed 2016·Granted May 30, 2017·1 cites·14 claims
- 1978US9265888B2Needle-free injectors and design parameters thereof that optimize injection performanceZOGENIX INC·Filed 2014·Granted Feb 23, 2016·7 cites·5 claims
- 2076US2022370381A1Compositions and methods for treating seizure disordersZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 2176US2022280646A1Compositions and methods involving polymer, solvent and high viscosity liquid carrier materialDURECT CORP·Filed 2022·Application pending·0 cites
- 2275US2023076320A1Norfenfluramine to treat dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 2374US2020085829A1Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2019·Application pending·0 cites
- 2473US2019091174A1Method of reducing seizure type experienced by a dravet patientZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 2572US11285217B2Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2020·Granted Mar 29, 2022·0 cites·20 claims
- 2671US2019091176A1Method of treating selected patient population experiencing dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 2771US2020276136A1Method of treating selected patient population experiencing dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2020·Application pending·0 cites
- 2870US2023093150A1Changing cognitive function with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 2968US2018140605A1Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2018·Application pending·0 cites
- 3067US2019091173A1Method of increasing time between convulsive seizuresZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 3167US2020297665A1Compositions and methods for treating seizure disordersZOGENIX INTERNATIONAL LTD·Filed 2020·Application pending·0 cites
- 3267US2019125697A1Method of reduction in convulsive seizure frequencyZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 3366US6830744B2Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2bARADIGM CORP·Filed 2002·Granted Dec 14, 2004·1 cites·34 claims
- 3466US2022226262A1Methods of treating doose syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 3566US2018092864A1Compositions and methods for treating seizure disordersZOGENIX INTERNATIONAL LTD·Filed 2017·Application pending·0 cites
- 3665US2019091177A1Method of treating selected patient population experiencing dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 3765US2017143721A1Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2017·Application pending·0 cites
- 3864US2019091175A1Method of reduction medication in treating dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 3963US2018055789A1Formulation for inhibiting formation of 5-ht2b agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2017·Application pending·0 cites
- 4063US2019255179A1Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialDURECT CORP·Filed 2019·Application pending·0 cites
- 4160US2020170965A1Methods of treating doose syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4257US2020306210A1Changing cognitive function with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2019·Application pending·0 cites
- 4354US2019091179A1Congnitive function with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4453US2014308352A1Compositions and methods involving polymer, solvent, and high viscosity liquid carrier materialZOGENIX INC·Filed 2014·Application pending·0 cites
- 4553US2005232899A1Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2bARADIGM CORP·Filed 2004·Application pending·0 cites
- 4653US2021113495A1Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertensionZOGENIX INTERNATIONAL LTD·Filed 2019·Application pending·0 cites
- 4751US2019083425A1Formulation for inhibiting formation of 5-ht2b agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4849US2017065771A1Piston closures for drug delivery capsulesZOGENIX INC·Filed 2016·Application pending·0 cites
- 4949US2014142500A1Piston closures for drug delivery capsulesZOGENIX INC·Filed 2013·Application pending·0 cites
- 5046US2019247333A1Method of reduction in convulsive seizure frequencyZOGENIX INTERNATIONAL LTD·Filed 2019·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →